Rwanda’s Health Ministry has signed a direct supply agreement with Swiss generics giant Sandoz, securing access to approximately 60 essential medicines, including antibiotics and cancer drugs for Rwanda and selected African partner countries.
The deal, signed in Kigali on April 15, 2026, makes Rwanda the first African government to enter a direct manufacturing-and-supply partnership with Sandoz one of the last remaining European companies capable of producing antibiotics from start to finish.
Medicines will be shipped from Sandoz’s Kundl facility in Austria, which the company describes as the last major end-to-end penicillin antibiotic manufacturing network left in either Europe or the United States.
Rwanda’s Health Minister, Dr. Sabin Nsanzimana, framed the deal squarely within the country’s broader health ambitions. “Rwanda is among the countries in Sub-Saharan Africa that reimburse cancer treatments through its public health system,” he said.
“This partnership reflects our efforts to work with established biosimilar and generic manufacturers to expand access to quality, affordable cancer care and essential antibiotic therapies. Through this agreement, Rwanda aims to support improved access to treatment for patients within Rwanda and across the African Union.” He added.
This agreement did not come out of nowhere. The deal follows the publication last August of the Alpbach Communiqué, a cross-sectoral, multinational commitment signed in Tyrol, Austria, to secure EU-based antibiotic supply for both Europe and partner regions.
That Communiqué was endorsed by Sandoz and supported by the Rwandan government.
In other words, Rwanda was in the room when this framework was built, and is now the first country to translate it into an operational agreement. That is a deliberate, strategic sequence not a coincidence.
Sandoz’s Chief Transformation and Growth Officer, Simon Goeller, called the deal “a first step towards a sustainable regional procurement model for affordable, high-quality medicines,” adding that it represents “good news for Rwanda, for Africa, and for our Kundl site.”
The timing is no accident. Rwanda hosts the African Medicines Agency (AMA) the African Union’s continental drug regulatory body, making Kigali the natural anchor for any serious pharmaceutical partnership targeting the continent.
Rwanda has emerged as a continental hub for medical innovation, already hosting the International Vaccine Institute’s Africa office and the African Pharmaceutical Technology Foundation, institutions that together provide the infrastructure and legal environment to anchor the AMA’s work.
This deal sits on top of that foundation. Rwanda has been methodically building pharmaceutical credibility domestically through the revival of Labophar, its oldest drug manufacturer, and regionally through the AMA hosting role.
Rwanda’s pharmaceutical market is projected to reach $125 million in 2025, and the government has made pharmaceutical sovereignty a national priority after spending an estimated $260 million on drug imports over the past five years.
For Sandoz, the logic is equally clear. Rwanda, as a regional distribution hub and home to the African Medicines Agency, offers a committed and strategically positioned partner for reliable supply of affordable, high-quality medicines while giving Sandoz additional volume to keep its critical Kundl manufacturing operations viable.
About the Author
